Enrollment is now open across all 38 clinical sites in the Phase 2b trial testing pirepemat (previously known as…
Articles by Patricia Inácio, PhD
Alterity Therapeutics’ new Phase 2 clinical trial testing ATH434 in patients with multiple system atrophy (MSA), a form…
The first patient has been dosed in a Phase 2 trial testing BIA 28-6156, Bial’s investigational therapy for…
NurrOn Pharmaceuticals has partnered with South Korean HanAll Biopharma and Daewoong Pharmaceutical to continue developing its candidate…
The Michael J. Fox Foundation (MJFF) is partnering with H1 to enhance the connections between physicians, researchers and patients…
The natural brain-produced steroid pregnenolone showed benefits in a rat model of Parkinson’s disease, where it was found…
The Van Andel Institute has awarded scientist Virginia M.Y. Lee the 2023 Jay Van Andel Award for Outstanding…
NeuroRPM, an artificial intelligence (AI)-powered app designed to continuously monitor hallmark symptoms of Parkinson’s disease has been cleared for…
Note: This story was updated March 24, 2023, to correct the name of CND Life Sciences. CND Life Sciences…
People with physical frailty have a nearly twofold higher risk of developing Parkinson’s disease than those who aren’t frail,…